4-(3-磺酰基苯基)氨基-6-甲酰基吡咯并［2,3-d］嘧啶类化合物的设计、合成与生物活性

乔佳男; 王庭芳; 张灿

doi:10.11665/j.issn.1000-5048.20170508

4-(3-磺酰基苯基)氨基-6-甲酰基吡咯并［2,3-d］嘧啶类化合物的设计、合成与生物活性

中国药科大学新药研究中心，江苏省代谢性疾病重点实验室

基金项目: 国家自然科学基金资助项目(No.81503003)

计量
- 文章访问数: 962
- HTML全文浏览量: 0
- PDF下载量: 1573
出版历程
- 刊出日期: 2017-10-24

Design, synthesis and bioactivities of 4-(3-sulfonylbenzene)amino-6-formylpyrrole［2, 3-d］ pyrimidine derivatives

摘要

摘要: 以JAK2抑制剂baricitinib和fedratinib为先导化合物，运用分子杂交药物设计原理，设计并合成了17个以4-(3-磺酰基苯基)氨基-6-甲酰基吡咯并［2，3-d］嘧啶( 3 )为母核、结构新颖的目标化合物，并通过JAK2激酶和粒细胞-巨噬细胞集落刺激因子(GM-CSF)诱导的TF-1细胞对所合成的化合物进行了活性测试。结果显示，多数化合物具有JAK2抑制活性，其中化合物( 31 )表现出较好的JAK2激酶活性(IC₅₀=0.009 μmol/L)和GM-CSF诱导的TF-1细胞抑制活性(IC₅₀=0.136 μmol/L)，表明该化合物具有潜在的研发价值。
- 磺酰基 /
- 吡咯并嘧啶 /
- JAK2抑制剂 /
- 合成 /
- 生物活性
Abstract: Taking JAK2 inhibitor baricitinib and fedratinib as the lead compounds, to design the novel 4-(3-sulfonylbenzene)amino-6-formylpyrrole［2, 3-d］ pyrimidine JAK2 inhibitors nucleus using the molecular hybrid drug design principle. 17 target compounds were synthesized by derivatization of sulfonyl and formyl groups respectively. We used JAK2 kinase and GM-CSF-induced TF-1 cells to measure the activities of compounds. The results showed that most compounds had JAK2 inhibitory activities. Among them, compound 31 had excellent inhibitory activity on JAK2 kinase( IC₅₀=0. 009 μmol/L )and GM-CSF-induced TF-1 cells(IC₅₀=0. 136 μmol/L), which proved that the compound had potential research and development value.
- sulfonyl /
- pyrrolopyrimidine /
- JAK2 inhibitors /
- synthesis /
- bioactivity

HTML全文

参考文献(15)

[1]	Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms[J].Blood,2014,123(14):2220-2228.
[2]	Lundberg P,Takizawa H,Kubovcakova L,et al.Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F[J].J Exp Med,2014,211(11):2213-2230.
[3]	Levine RL. Another piece of the myeloproliferative neoplasms puzzle[J].N Engl J Med,2013,369(25):2451-2452.
[4]	Stark GR,Darnell JE Jr.The JAK-STAT pathway at twenty[J].Immunity,2012,36(4):503-514.
[5]	Aaronson DS,Horvath CM.A road map for those who don′t know JAK-STAT[J].Science,2002,296(5573):1653-1655.
[6]	Levine RL. Another piece of the myeloproliferative neoplasms puzzle[J].N Engl J Med,2013,369(25):2451-2452.
[7]	Wernig G,Kharas MG,Okabe R,et al.Efficacy of TG101348,a selective JAK2 inhibitor,in treatment of a murine model of JAK2V617F-induced polycythemia vera[J].Cancer Cell,2008,13(4):311-320.
[8]	Williams R. Discontinued in 2013: oncology drugs[J]. Expert Opin Investig Drugs,2015,24(1):95-110.
[9]	Zhang Q,Zhang Y,Diamond S,et al.The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake:a putative mechanism for the onset of Wernicke′s encephalopathy[J].Drug Metab Dispos,2014,42(10):1656-1662.
[10]	Genovese MC,Kremer J,Zamani O,et al.Baricitinib in patients with refractory rheumatoid arthritis[J].N Engl J Med,2016,374(13):1243-1252.
[11]	Schumock GT,Li EC,Suda KJ,et al.National trends in prescription drug expenditures and projections for 2014[J].Am J Health Syst Pharm,2014,71(6):482-499.
[12]	Wang T,Liu X,Hao M,et al.Design,synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors[J].Bioorg Med Chem Lett,2016,26(12):2936-2941.
[13]	Ning CQ,Lu C,Hu L,et al.Macrocyclic compounds as anti-cancer agents:design and synthesis of multi-acting inhibitors against HDAC,FLT3 and JAK2[J].Eur J Med Chem,2015,95:104-115.
[14]	Hanan EJ,van Abbema A,Barrett K,et al.Discovery of potent and selective pyrazolopyrimidine Janus kinase 2 inhibitors[J].J Med Chem,2012,55(22):10090-10107.
[15]	Changelian PS,Flanagan ME,Ball DJ,et al.Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor[J].Science,2003,302(5646):875-878.

施引文献

资源附件(0)

计量

文章访问数: 962
HTML全文浏览量: 0
PDF下载量: 1573
被引次数: 0

4-(3-磺酰基苯基)氨基-6-甲酰基吡咯并［2,3-d］嘧啶类化合物的设计、合成与生物活性

计量

出版历程

Design, synthesis and bioactivities of 4-(3-sulfonylbenzene)amino-6-formylpyrrole［2, 3-d］ pyrimidine derivatives

计量

出版历程

目录